Floatz logo

Burosumab

Epidermal Nevus Syndrome (ENS)

Kyowa Kirin, Inc.monoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Epidermal Nevus Syndrome (ENS) cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Burosumab is also rated in:

rareDormant
BB
Indicative ·
65 / 100
View asset →
X-linked dominant hypophosphatemic ricketsDormant
BB
Indicative ·
65 / 100
View asset →
hypophosphatemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →